StockMarketWire.com - Mereo BioPharma Group said it collected positive top-line data from a trail of a first-line therapy for acute exacerbations of chronic obstructive pulmonary disease.

The phase two clinical trial with BCT-197 was a double-blind, randomised, placebo-controlled clinical study.

"These are exciting results," said Wisia Wedzicha, a principal investigator in the trial.


At 9:48am: [LON:MPH] Mereo Biopharma Group Ltd share price was +15p at 330p



Story provided by StockMarketWire.com